|
Home : Unsafe Drugs : Avandia : News Articles : GSK profits slump amid ongoing Avandia woes | InPharm GSK profits slump amid ongoing Avandia woes | InPharm
Profits after tax plummeted 56% to £3 billion for 2010 following a number of large legal charges, including a £2.2 billion hit relating to Avandia. “There is no doubt that the scale of legal provisioning that has been required is significant,†said GSK’s chief ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




